Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15. SPC-15 is an intranasal 5-HT4 receptor agonist designed to target post-traumatic stress disorder (PTSD) and other stress-induced psychiatric disorders. The Canadian patent allowance provides Silo with exclusive rights to develop, manufacture, and commercialize SPC-15 in Canada through its broader license agreement with Columbia University.
This development is significant for Silo as it strengthens the company's intellectual property portfolio in key international markets. Corresponding patents have already been granted in Europe, and additional applications are advancing in other regions. The Canadian allowance, coupled with the European grant, provides a robust foundation for the global commercialization of SPC-15. The company intends to leverage the FDA's streamlined 505(b)(2) regulatory pathway for SPC-15, which could shorten clinical timelines and reduce development costs, potentially accelerating the time to market for this promising therapy.
The importance of this patent allowance extends beyond Silo's immediate pipeline. PTSD is a major mental health condition affecting millions worldwide, and current treatment options are often limited or associated with significant side effects. SPC-15, as an intranasal formulation, offers a novel approach that may improve patient compliance and onset of action. The patent protection in Canada and Europe enhances the asset's commercial viability and provides a competitive edge in the marketplace.
Silo Pharma's portfolio also includes other innovative programs, such as SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company collaborates with leading universities and laboratories to advance its research. The Canadian patent allowance is a testament to the strength of Silo's scientific collaborations and its commitment to addressing underserved medical conditions.
Investors and stakeholders can view the full press release for more details at https://ibn.fm/L3Jm4. For the latest news and updates on Silo Pharma, visit the company's newsroom at https://ibn.fm/SILO.
